New Search

If you are not happy with the results below please do another search

Archive for category: News

23

Video – how the LRC-TriCEPS technology works

Dualsystems Biotech AG Press Release How the LRC-TriCEPS technology works (Video) Zürich Switzerland – June 23, 2014 – Dualsystems Biotech AG offers the most advanced technology for identifying receptor(s) for orphan ligands. The ligand-receptor capture technology (LRC-TriCEPS) is an innovative and conceptually new approach for the unbiased discovery of cell surface interactions of ligands ranging…

24

Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology

Dualsystems Biotech AG Press Release Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology Schlieren, Switzerland, January 2014: – Dualsystems Biotech AG has announced it will collaborate with another Swiss laboratory, Institute for Biopharmaceutical Research (IBR Inc.) to validate the CaptiRec Triceps/Ligand Receptor Capture Technology. This technology is used to…

26

Dualsystems closes Series C Financing Round

Dualsystems Biotech  has closed a Series C financing round with support from existing and new investors to implement and drive forward its new business strategy in mass spectrometry based protein interaction discovery.

28

Licensing Agreement with ETH Zurich on LRC technoloy

Dualsystems Biotech closes Licensing Agreement with ETH Zurich on Ligand Receptor Capture (LRC) technology Dualsystems Biotech has licensed an innovative technology to discover cell-surface receptors for a vast range of ligands of interest. LRC is centered around an innovative trifunctional chemoproteomic reagent named TriCEPS, which enables the unbiased identification of cell surface receptors for many…